Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 145,407 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: NAFLD, Obesity, Nutritional and Metabolic Diseases
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Davis, California

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, cisplatin, cyclophosphamide, etoposide, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 10 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 29
States / cities: Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more

Conditions: Pericoronitis
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Venous Reflux, Chronic Venous Insufficiency
Interventions: Venclose System (digiRF generator w EVSRF catheter), Venclose MAVEN System (digiRF generator w MAVEN catheter); Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Thornton, Colorado • Kailua, Hawaii • Roseville, Michigan + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Roseville, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 3,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dysphagia, Oral Phase, Stroke, Ischemic
Interventions: Lingual Endurance Training; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Malignant Melanoma Stage III, Malignant Melanoma Stage IV
Interventions: IL15-DC Vaccine; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Kidney Stone, Ureteral Stone
Interventions: Dusting without Moses 2.0 Modulation, Dusting with Moses 2.0 Modulation, Moses 2.0 Modulation; Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Respiratory Tract Infections, Gastrointestinal Infection
Interventions: BioFire test platform; Diagnostic Test
Lead sponsor: BioFire Diagnostics, LLC; Industry
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gastroesophageal Reflux, Presumed Sepsis, Patent Ductus Arteriosus, Chronic Lung Disease, Neurodevelopmental Impairment
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Up to 5 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: CTE, TBI (Traumatic Brain Injury)
Interventions: [F-18]FDDNP; Radiation
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Mild Cognitive Impairment
Interventions: Plasmapheresis, Plasma infusion; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Ovarian Cancer
Interventions: cisplatin liposomal; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Computer attention training systems for children with ADHD; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 10 Years to 15 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Focal Encephalitis, Rasmussen's Encephalitis
Interventions: Rituximab; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 5 Years to 25 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Follicular Lymphoma, Endometrial Cancer
Interventions: Copanlisib, Ketogenic Diet; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: VRC-HIVADV014-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 20 Years to 37 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: iPrEP, Usual Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Arthritis
Interventions: NSAID, tanezumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 250
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more

Conditions: Dry Eye, Contact Lens Complication
Interventions: DT1 Sphere Contact Lenses; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Birmingham, Alabama • Pittsburg, Kansas • Granville, Ohio + 1 more

Conditions: Glaucoma
Interventions: Xalatan, Travatan Z; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Brain and Central Nervous System Tumors
Interventions: nelfinavir mesylate, temozolomide, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fibromyalgia
Interventions: Duloxetine, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 33
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more

Search by objective public record fields.

The Effect of Time-restricted Eating on Liver Metabolism

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Third Molar Clinical Trials: Pericoronitis Studies

Venclose digiRF System Post Market Study

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Evaluation of Patients With Immune Function Abnormalities

Lingual Endurance Exercise in Treating Post-Stroke Dysphagia

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Ureteroscopy With High-powered Holmium:Yag Laser Lithotripsy With and Moses On or Moses Off

Specimen Collection and Transport Workflow Evaluations for CLIA-waived Molecular Testing

Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer

A Trial of Computer-based Attention-training Systems in Children With Attention Deficit Hyperactivity Disorder (ADHD)

A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis

Study of Copanlisib and Ketogenic Diet

Vaccine Treatment for HIV-Infection

Leveraging the Emergency Department to Engage African American Women in HIV Pre-Exposure Prophylaxis

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

Dailies Total 1 Sphere Contact Lenses

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome